Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850203 | 0.93 | CNR1 (0.47) | BRAFRAF1CNR1HPGDALDH1A1 | |
| SCHEMBL12856511 | 0.88 | RAF1 (0.51) | BRAFRAF1CNR1HPGDALDH1A1 | |
| SCHEMBL5850170 | 0.82 | BRAF (0.56) | BRAFRAF1 | |
| SCHEMBL5848384 | 0.82 | BRAF (0.59) | BRAFRAF1 | |
| SCHEMBL6580921 | 0.76 | BRAF (0.67) | BRAFRAF1 | |
| SCHEMBL5848398 | 0.73 | MAPK13 (0.53) | BRAFRAF1HPGDALDH1A1KDM4E | |
| SCHEMBL2029325 | 0.73 | MAPK14 (0.56) | BRAFRAF1HPGDALDH1A1KDM4E | |
| SCHEMBL8603189 | 0.71 | MAPK13 (0.50) | BRAFRAF1HPGDALDH1A1KDM4E | |
| SCHEMBL12856388 | 0.70 | BRAF (0.90) | BRAFRAF1 | |
| SCHEMBL6175640 | 0.69 | BRAF (0.43) | BRAFCYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | claimed |
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | disclosed |
| EP-1261602-B1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | GAIBA ALESSANDRA (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885CNR1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.